GO:1903312 negative regulation of mRNA metabolic process: mRNA Stability and Decay Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903312 describes any process that stops, prevents, or reduces the frequency, rate, or extent of mRNA metabolic process, encompassing mRNA stability, decay, and turnover [1,3].
• Key molecular players include the CCR4-NOT deadenylase complex, RNA-binding proteins, and m6Am/m6A RNA modifiers such as PCIF1 and TET2 [3,5,2].
• Dysregulation of this process is linked to lymphocyte development, head and neck squamous cell carcinoma, and pathogen-induced myelopoiesis [3,5,2].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators of mRNA metabolism [3,5].
• Transcriptional pausing by NELF and hypoxia-induced NEP repression illustrate layered control of mRNA fate [6,7].
• Research methods include RNA-seq, Ribo-seq, m6A/m6Am mapping, and proteomics to quantify mRNA stability and translation [5,2].
Description
The Gene Ontology term GO:1903312, negative regulation of mRNA metabolic process, defines any biological process that stops, prevents, or reduces the frequency, rate, or extent of mRNA metabolic process [1,3]. This term captures a critical layer of post-transcriptional control that determines the lifespan and availability of messenger RNAs for translation, thereby shaping gene expression programs in development, immunity, and disease [3,4]. Unlike transcriptional regulation, which sets the initial RNA output, negative regulation of mRNA metabolism acts after synthesis to fine-tune protein production, often through deadenylation, decapping, and exonucleolytic decay [3,8]. Researchers study GO:1903312 because mRNA stability and decay are central to rapid cellular responses, such as immediate-early gene induction and immune cell differentiation [6,3]. For example, the CCR4-NOT complex catalyzes mRNA deadenylation to limit lymphocyte development, and its disruption alters early B- and T-cell programs. Similarly, m6Am modification by the CTBP2-PCIF1 complex modulates mRNA stability in head and neck squamous cell carcinoma, linking RNA modification to oncogenesis. These findings underscore that negative regulation of mRNA metabolic process is not a passive degradation pathway but a dynamic, regulated network [2,5]. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:1903312, including its definition, molecular mechanisms, key genes, disease relevance, and experimental models. It is intended for scientists designing CRISPR-based studies to interrogate mRNA stability and decay in human disease [3,5,8].
negative regulation of mRNA metabolic process At A Glance
| GO ID | GO:1903312 |
|---|---|
| GO term | negative regulation of mRNA metabolic process |
| Ontology | biological_process |
| Synonym | down regulation of mRNA metabolic process; inhibition of mRNA metabolic process; negative regulation of mRNA metabolism |
| Major function | Reduces mRNA stability, decay, or turnover to control gene expression post-transcriptionally [1,3] |
| Related processes | mRNA deadenylation, decapping, exonucleolytic decay, m6A/m6Am modification [3,5,8] |
| Key regulators | CCR4-NOT complex, PCIF1, TET2, NELF, NEP [3,5,2,6,7] |
| Disease links | Lymphocyte development, head and neck squamous cell carcinoma, pathogen-induced myelopoiesis [3,5,2] |
What Is GO:1903312?
GO:1903312, negative regulation of mRNA metabolic process, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of mRNA metabolic process. In practice, this includes mechanisms that shorten mRNA half-life, inhibit mRNA processing or modification, or reduce the overall turnover of messenger RNAs, thereby limiting their availability for translation [1,3,8].
Why Is negative regulation of mRNA metabolic process Important in Cell Biology?
Negative regulation of mRNA metabolic process is essential for maintaining proper gene expression timing and magnitude; its dysregulation can lead to developmental defects, immune dysfunction, and cancer [3,5,2]. Understanding this process provides mechanistic insight into how cells rapidly adjust proteomes without new transcription, and it offers therapeutic targets for diseases driven by aberrant mRNA stability [5,7].
• Controls mRNA half-life and translation efficiency, enabling rapid cellular responses [4,6].
• Regulates early lymphocyte development through CCR4-NOT-mediated mRNA decay.
• Modulates oncogenic pathways via m6Am modification in head and neck squamous cell carcinoma.
• Links RNA oxidation by TET2 to pathogen-induced myelopoiesis.
• Influences immediate-early gene expression through transcriptional pausing by NELF.
• Hypoxia-induced repression of NEP alters mRNA metabolism in prostate cells.
• Provides targets for CRISPR screens to identify negative regulators of mRNA stability [3,5].
• Relevant to bacterial RNA processing and degradation mechanisms.
• Impacts mRNA modification and stability in cancer and immune cells [5,2].
• Enables development of RNA-based therapeutics targeting mRNA turnover [1,5].
What Happens During negative regulation of mRNA metabolic process?
Deadenylation and Decapping
In simple terms: The mRNA loses its protective tail and cap, marking it for destruction.
Negative regulation of mRNA metabolic process often begins with deadenylation, where the poly(A) tail is shortened by deadenylase complexes such as CCR4-NOT. This step is rate-limiting for mRNA decay and is tightly regulated during lymphocyte development. Following deadenylation, decapping enzymes remove the 5' cap, exposing the transcript to exonucleases.
Exonucleolytic Degradation
In simple terms: Enzymes chew up the mRNA from one end after the cap or tail is removed.
Once deadenylated and decapped, mRNAs are degraded by 5' to 3' or 3' to 5' exonucleases. In bacteria, RNase E and other ribonucleases mediate RNA processing and degradation, illustrating conserved principles of negative regulation. In eukaryotes, the exosome complex carries out 3' to 5' degradation.
RNA Modification and Stability Control
In simple terms: Chemical tags on mRNA can make it more or less stable.
Modifications such as m6Am and m6A influence mRNA stability. The CTBP2-PCIF1 complex regulates m6Am modification, affecting mRNA fate in head and neck squamous cell carcinoma. TET2-mediated mRNA oxidation promotes myelopoiesis during pathogen infection, linking RNA modification to immune cell production.
Transcriptional Pausing and Immediate-Early Genes
In simple terms: RNA polymerase can pause, affecting how much mRNA is made and how long it lasts.
NELF-mediated transcriptional pausing regulates immediate-early expression of junB, demonstrating crosstalk between transcription and mRNA metabolism. This pausing can influence the pool of mRNA available for negative regulation.
Hypoxia and NEP Repression
In simple terms: Low oxygen can reduce a protein that normally controls mRNA processing.
Hypoxia negatively regulates NEP expression, which in turn affects mRNA metabolism in prostate cells. This illustrates how environmental cues modulate negative regulation of mRNA metabolic process.
Key Genes Involved in GO:1903312 negative regulation of mRNA metabolic process
The following genes and proteins are experimentally implicated in negative regulation of mRNA metabolic process, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCR4-NOT complex | Catalyzes mRNA deadenylation to promote decay | Regulates early lymphocyte development; knockout models show altered B/T cell programs |
| PCIF1 | m6Am methyltransferase; part of CTBP2-PCIF1 complex | Modulates mRNA stability in head and neck squamous cell carcinoma |
| CTBP2 | Forms complex with PCIF1 to regulate m6Am | Oncogenic role via mRNA modification |
| TET2 | Oxidizes mRNA to promote myelopoiesis | Links RNA oxidation to pathogen-induced immune responses |
| NELF | Induces transcriptional pausing at immediate-early genes | Regulates junB expression and mRNA availability |
| NEP | Negatively regulated by hypoxia; affects mRNA metabolism | Prostate cancer biology and hypoxia response |
| MDM4 | Regulated at mRNA level; affects p53 pathway | Cancer therapy target; mRNA stability control |
| RNase E | Bacterial endonuclease for RNA degradation | Model for conserved RNA decay mechanisms |
| Exosome complex | 3' to 5' exonucleolytic degradation | General mRNA turnover |
| Decapping enzymes | Remove 5' cap to allow degradation | Rate-limiting step in mRNA decay |
| Poly(A) binding proteins | Protect poly(A) tail; regulate deadenylation | Modulate translation and stability |
| miRNA/RISC | Guide mRNA cleavage or repression | Specific negative regulation of mRNA metabolism |
| RNA-binding proteins | Recognize sequence elements to recruit decay machinery | Diverse roles in mRNA fate |
| JunB | Immediate-early gene regulated by NELF pausing | Model for transcriptional and post-transcriptional control |
| p53 | Indirectly affected by MDM4 mRNA stability | Cancer pathway |
| m6A writers/erasers | Modify mRNA to affect stability | Emerging targets in cancer |
| TUTases | Add uridines to mRNA 3' end, promoting decay | RNA tailing in degradation |
How Is negative regulation of mRNA metabolic process Regulated?
Negative regulation of mRNA metabolic process is itself regulated at multiple levels. The CCR4-NOT complex is recruited to specific mRNAs by sequence-specific RNA-binding proteins, and its activity can be modulated by signaling pathways. RNA modifications such as m6Am and m6A are dynamically added and removed by writer and eraser enzymes, affecting mRNA stability. TET2-mediated oxidation of mRNA is induced during pathogen infection, linking immune signaling to mRNA decay. Transcriptional pausing by NELF can influence the pool of mRNA available for negative regulation. Hypoxia represses NEP expression, altering mRNA metabolism. These layers of regulation ensure precise control of mRNA fate in response to developmental and environmental cues [1,4].
negative regulation of mRNA metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCIF1 | Head and neck squamous cell carcinoma | Knockout in HNSCC cell lines; m6Am mapping |
| CCR4-NOT | Lymphocyte development disorders | Conditional knockout in mouse T/B cells |
| TET2 | Pathogen-induced myelopoiesis | Tet2 knockout mice; infection models |
| MDM4 | Cancer (p53 pathway) | Overexpression and knockdown in cancer cells |
| NEP | Prostate cancer / hypoxia | Hypoxia-treated prostate cancer cells; NEP knockdown |
Cancer
Dysregulation of negative regulation of mRNA metabolic process contributes to cancer. The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma, affecting mRNA stability and tumor progression. MDM4, an oncogene, is regulated at the mRNA level, and its stability influences p53 pathway activity. Targeting mRNA decay pathways may offer therapeutic opportunities [5,1].
Immune and Hematological Disorders
CCR4-NOT-mediated mRNA decay is essential for early lymphocyte development; its disruption leads to altered B- and T-cell differentiation. TET2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation, linking mRNA modification to immune cell production. These findings implicate negative regulation of mRNA metabolism in immune disorders and hematological malignancies [3,2].
Hypoxia and Prostate Cancer
Hypoxia negatively regulates NEP expression, which in turn affects mRNA metabolism in prostate cells. This pathway may contribute to prostate cancer progression under low oxygen conditions.
From negative regulation of mRNA metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PCIF1 loss alter m6Am and mRNA stability? | CRISPR knockout of PCIF1 in HNSCC cells |
| Is CCR4-NOT required for lymphocyte development? | Conditional knockout of CCR4-NOT subunits in mice |
| Does TET2-mediated mRNA oxidation promote myelopoiesis? | Tet2 knockout mice with pathogen infection |
| Does NEP repression affect mRNA metabolism under hypoxia? | NEP knockdown or overexpression in prostate cells |
| Does NELF pausing regulate junB mRNA levels? | NELF knockout or point mutation in cell lines |
| Can MDM4 mRNA stability be modulated? | MDM4 3'UTR knock-in reporters |
How to Study the negative regulation of mRNA metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Steady-state mRNA levels and half-lives | Global mRNA stability profiling |
| Ribo-seq | Ribosome occupancy and translation | Translation efficiency after decay |
| m6A/m6Am mapping | RNA modification sites | Linking modification to stability |
| Proteomics | Protein interactions and abundance | Identifying decay complex components |
| CRISPR screens | Gene essentiality for mRNA stability | Discovering negative regulators [3,5] |
| Northern blot | Specific mRNA size and abundance | Validating decay intermediates |
| Reporter assays | 3'UTR-mediated stability | Testing regulatory elements |
RNA-seq and Stability Profiling
RNA-seq after transcriptional inhibition (e.g., actinomycin D) measures mRNA half-lives and identifies transcripts subject to negative regulation [3,5]. This method quantifies global changes in mRNA metabolism.
m6A/m6Am Mapping
Antibody-based or chemical mapping of m6A and m6Am modifications reveals how RNA modifications affect mRNA stability [5,2]. These techniques link writers/erasers to negative regulation.
Ribo-seq and Translation Profiling
Ribo-seq measures ribosome occupancy to assess how mRNA decay affects translation. It complements RNA-seq to distinguish stability from translation efficiency.
Proteomics and Interactomics
Mass spectrometry identifies proteins associated with mRNA decay complexes, such as CCR4-NOT and exosome [3,8]. This reveals regulatory networks.
How CRISPR Can Be Used to Study GO:1903312 negative regulation of mRNA metabolic process
Knockout
CRISPR knockout of genes such as PCIF1 or CCR4-NOT subunits can reveal their requirement for negative regulation of mRNA metabolic process [3,5]. For example, PCIF1 knockout reduces m6Am and alters mRNA stability in HNSCC cells.
Point Mutation
Point mutations in catalytic residues of deadenylases or methyltransferases can dissect enzymatic versus scaffolding functions [3,5]. Such models help determine whether mRNA decay activity is essential.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of mRNA stability in live cells. For instance, MDM4 3'UTR knock-in reporters can measure changes in mRNA half-life.
Overexpression
Overexpression of negative regulators like TET2 or NEP can enhance mRNA decay and suppress target transcripts [2,7]. This approach tests sufficiency in disease models.
How EDITGENE Supports negative regulation of mRNA metabolic process Research
Researchers studying negative regulation of mRNA metabolic process-related genes often need to determine whether a candidate gene is causally involved in mRNA stability, decay, or turnover. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mRNA metabolic process research.
Frequently Asked Questions About negative regulation of mRNA metabolic process
What is GO:1903312?
GO:1903312 is the Gene Ontology term for negative regulation of mRNA metabolic process, describing any process that stops, prevents, or reduces the frequency, rate, or extent of mRNA metabolic process [1,3].
What genes are involved in negative regulation of mRNA metabolic process?
Key genes include CCR4-NOT complex subunits, PCIF1, CTBP2, TET2, NELF, NEP, and MDM4, among others [3,5,2,6,7,1].
How does negative regulation of mRNA metabolic process work?
It typically involves deadenylation, decapping, and exonucleolytic degradation of mRNAs, often guided by RNA-binding proteins and RNA modifications [3,8,5].
Why is negative regulation of mRNA metabolic process important?
It controls mRNA half-life and translation, influencing development, immunity, and cancer [3,5,2].
What diseases are linked to negative regulation of mRNA metabolic process?
Cancer, immune disorders, and hypoxia-related diseases have been linked to dysregulation of this process [5,3,7].
What methods study negative regulation of mRNA metabolic process?
RNA-seq, Ribo-seq, m6A/m6Am mapping, proteomics, and CRISPR screens are commonly used [3,5,4].
Can CRISPR be used to study negative regulation of mRNA metabolic process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of genes involved [3,5,1].
What is the role of CCR4-NOT in mRNA metabolism?
CCR4-NOT catalyzes mRNA deadenylation, promoting decay and regulating lymphocyte development.
How does m6Am affect mRNA stability?
m6Am modification, regulated by PCIF1, can influence mRNA stability and is implicated in head and neck squamous cell carcinoma.
What is the connection between TET2 and mRNA metabolism?
TET2 oxidizes mRNA to promote myelopoiesis during pathogen infection, linking RNA modification to immune responses.
Conclusion
GO:1903312, negative regulation of mRNA metabolic process, is a fundamental post-transcriptional control mechanism that determines mRNA fate and protein output. Its dysregulation contributes to cancer, immune disorders, and other diseases, making it a rich area for research [3,5,2]. CRISPR-based models and multi-omics methods are powerful tools to dissect this process and identify therapeutic targets [3,5,1].
References
- 1. Markey MP. 2011. Regulation of MDM4.. Front Biosci (Landmark Ed) 16(3):1144-56 PMID: 21196223
- 2. Shen Q et al.. 2018. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation.. Nature 554(7690):123-127 PMID: 29364877
- 3. Akiyama T et al.. 2021. Regulation of Early Lymphocyte Development via mRNA Decay Catalyzed by the CCR4-NOT Complex.. Front Immunol 12:715675 PMID: 34349771
- 4. Standart N et al.. 1994. Regulation of translation by specific protein/mRNA interactions.. Biochimie 76(9):867-79 PMID: 7880904
- 5. Li K et al.. 2023. The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma.. J Clin Invest 133(20) PMID: 37643007
- 6. Aida M et al.. 2006. Transcriptional pausing caused by NELF plays a dual role in regulating immediate-early expression of the junB gene.. Mol Cell Biol 26(16):6094-104 PMID: 16880520
- 7. Mitra R et al.. 2013. Negative regulation of NEP expression by hypoxia.. Prostate 73(7):706-14 PMID: 23138928
- 8. Trinquier A et al.. 2020. Regulation of RNA processing and degradation in bacteria.. Biochim Biophys Acta Gene Regul Mech 1863(5):194505 PMID: 32061882
